EMD Serono, USA
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Department: Protein Engineering and Antibody Technologies/ Antibody Technologies
Title: Head of Antibody Technologies (Billerica) | Associate Director
Start Date: September 5, 2000
Education: University of Nice-Sophia Antipolis (France) B.S. Biochemistry (1993), University of Nice-Sophia Antipolis (France) MS Cell Biology and Pharmacology (1994), University of Nice-Sophia Antipolis (France), PhD Molecular and cellular biology (1997), Postdoctoral: Albert Einstein College of Medicine, NY (1997-98), Dana-Farber Cancer Institute, Harvard Medical School, Boston (1998-2000)
What initially drew you to EMD Serono?
After working in an academic laboratory, I wanted the chance to apply the science I was doing in a way that it could help people and contribute to new therapies.
What do you like about working for this organization?
It seems like every day I learn something new. The science we do at EMD Serono is exciting and my colleagues are great!
What makes EMD Serono unique?
At EMD Serono, we are part of a larger, global organization,  and the employee base and work environment reflect that. It is very diverse –a mix of American and European culture.
What do you enjoy most about working as a researcher?
I still feel excited when I see great results or promising, new data.
Please describe your career path.
My career path has changed quite a bit since my doctoral studies. I never intended to end up in the U.S., however, because pharmaceutical industry is so concentrated in Boston there is great opportunity here. The only common line of study through my career has been oncology, a very complex and fascinating field where everything has to be discovered.

PERSONAL VISION

Christel chose to work in Antibody Technologies because it was fast moving and  an area of great focus for many companies. She says she also enjoys the challenges this field presents due to the continuously evolving technology used.

Christel hopes that her work will lead to the discovery of an antibody that could help patients and lead to new therapies.